What are the side effects of Osimertinib?
OsimertinibBelongs to the kinase inhibitor class of drugs. Osimertinib is suitable for patients with epidermal growth factor receptor (EGFR) exon19 deletion or exon21 Adjuvant therapy after tumor resection for patients with L858Rmutated non-small cell lung cancer (NSCLC), suitable for EGFRexon19 deletion or exon21 First-line treatment of patients with L858Rmutated metastatic non-small cell lung cancer. It is suitable for patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer whose disease has progressed during or after treatment with EGFRtyrosine kinase inhibitors (TKI).

Osimertinib(Osimertinib)What are the side effects?
Common side effects of osimertinib include lymphopenia (63%), thrombocytopenia (46%), anemia (43%), diarrhea (41%), < span>Skin rash (34%), Neutropenia (27%), Hypermagnesemia (27%), Hyponatremia (26%), Dry skin (< /span>23%), Nail toxicity (22%), Fatigue (22%), Hypoglycemia (20%), Eye disease (18% ), Decreased appetite (18%), Cough (17%), Nausea (16%), Stomatitis (15%), Constipation ( 14% n>10%), Hypokalemia (9%), Lymphopenia, grade 3 or grade 4 (8.2%
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)